Core Insights - Humacyte, Inc. is a biotechnology platform company focused on developing universally implantable, bioengineered human tissues at a commercial scale [2] Company Overview - Humacyte is developing acellular tissues to treat a variety of diseases, injuries, and chronic conditions [2] - The company received FDA approval for its acellular tissue engineered vessel (ATEV), Symvess, for vascular trauma in December 2024 [2] - ATEVs are in late-stage clinical trials for other vascular applications, including arteriovenous access for hemodialysis and peripheral artery disease [2] - Preclinical development is ongoing for coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and other novel cell and tissue applications [2] - The 6mm ATEV for AV access in hemodialysis was the first to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and also holds Fast Track designation [2] - The ATEV has received priority designation for vascular trauma treatment from the U.S. Secretary of Defense [2] Upcoming Events - Humacyte's management will participate in the TD Cowen 46th Annual Healthcare Conference on March 4, 2026, from 10:30-11:00 am Eastern Time [2] - The company will also participate in the Barclays 28th Annual Global Healthcare Conference with a fireside chat scheduled from 1:00-1:25 pm Eastern Time [2]